Carvedilol with midodrine vs carvedilol alone to prevent rebleeding in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if adding midodrine to carvedilol is better than carvedilol alone at preventing another bleed from varices in patients with cirrhosis who have had a high-risk variceal bleed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis and recently had a variceal bleed that was high-risk (based on liver disease severity and active bleeding seen during endoscopy).
- You are between 18 and 75 years old.
- You have not taken carvedilol, any non-selective beta blocker, or midodrine in the last 5 days.
- You do not have severely low heart rate (below 60 at rest) or low blood pressure (below 100/60 mm Hg).
- You do not have severe liver disease (MELD score above 30 or serum lactate above 12 mmol/L).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial compares two approaches to prevent future bleeding from enlarged veins in the esophagus (food pipe) in patients with liver cirrhosis who have already had one bleeding episode. You'll receive either an endoscopic procedure with medication or a minimally invasive vein procedure, to see which works better long-term.
This trial tests a slightly smaller TIPS stent (underdilated) against the standard size to see which is better at preventing another variceal bleed in people with cirrhosis and liver scarring. It aims to find the safest way to lower pressure in the veins while reducing side effects.
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
This trial compares two approaches to prevent first-time bleeding from enlarged veins in the food pipe (varices) in people with liver cancer and cirrhosis. One group receives a daily pill (carvedilol), and the other receives the pill plus a procedure (endoscopic banding) to tie off the veins.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.